GSK GlaxoSmithKline PLC
Company Analysis
Latest News
GSK reports positive Phase III RSV vaccine results in older adults
GSK reported promising results from a Phase III trial of its new RSV vaccine in older adults. The study involved more than 25,000 participants and met its...
GSK Wins FDA Approval for Jemperli, First Immunotherapy for Certain Rectal Cancers
GSK announced that the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab-gxly) for a specific type of locally advanced...
GSK Could Cut Up to 1,217 Belgium Jobs in Restructuring
GSK announced Wednesday that it could cut as many as 1,217 jobs in Belgium as part of its global restructuring plan. The proposed cuts would affect its...
🟢 GlaxoSmithKline is trading 5% up in after-hours trading
GlaxoSmithKline is trading 4.9% up at $48.80 in after-hours trading, with no reliable report explaining the rebound. - The regular-session close was $46.52 on...
GSK Advances Jemperli in Canada, Targeting Surgery-Free Rectal Cancer Treatment
GSK announced Thursday that Health Canada accepted its supplemental new drug submission for Jemperli (dostarlimab). The submission targets the treatment of...
GSK acquires $750 million Chimagen drug to expand blood cancer pipeline
GSK will acquire a preclinical T-cell engager for multiple myeloma from Chimagen Biosciences. The agreement includes an undisclosed upfront payment and up to...
🟢 GlaxoSmithKline is trading 4.07% up today after ARTEMIS-008 data showed 54% lower death risk
GlaxoSmithKline is trading 4.07% up at $50.09 after positive Phase III ARTEMIS-008 data showed Ris-Rez reduced death risk by 54% versus topotecan in relapsed...
🟢 GlaxoSmithKline is trading 4.17% up in pre-market after Ris-Rez reduced death risk 54% versus topotecan
GlaxoSmithKline is trading 4.17% up at $50.14 after positive Phase III Ris-Rez data reduced the risk of death by 54% versus topotecan in relapsed small-cell...
GSK’s Ris-Rez cuts lung cancer death risk 54% in Phase III trial
GSK announced positive Phase III trial results from China for its investigational antibody-drug conjugate, Ris-Rez. The drug reduced the risk of death by 54%...
🟢 GlaxoSmithKline is trading 6% up in after-hours trading amid broad market strength
GlaxoSmithKline is trading at $50.80, up 5.56% after the regular session closed at $48.12 on September 11, 2026, amid broad market strength. - The S&P 500,...
GSK signs $1.3 billion HUTCHMED deal, targeting KRAS-driven cancers
GSK secured an exclusive worldwide licensing agreement with HUTCHMED for the cancer therapy HMPL-A830. HUTCHMED will retain development and commercialization...
GSK’s Jemperli wins FDA priority review, potentially replacing rectal cancer surgery
The U.S. Food and Drug Administration (FDA) accepted GlaxoSmithKline’s application for Jemperli (dostarlimab) under Priority Review. This application seeks...
Dodge & Cox Reduces Stake in GSK by 17.8%
In a quarterly filing with the SEC, investment manager Dodge & Cox disclosed a reduction in its position in GSK PLC. The report, which covers the period ending...
GSK Secures Rights to Chugai’s Dengue Antibody, Targeting Global Health Threat
GSK plc secured an exclusive global license from Chugai Pharmaceutical Co Ltd for the anti-dengue antibody AID351. The agreement grants GSK full rights for the...
GSK Pharma Profit Climbs 15.7%, Driven by Vaccine and Medicine Sales
GlaxoSmithKline Pharmaceuticals reported a 15.7% year-over-year increase in consolidated net profit for the quarter ended June 30, 2026. Net profit reached...
GSK Targets $2.5B in Savings, Doubling Drug Trials Before Patent Expiry
GSK announced a three-year restructuring plan to save £1.9 billion ($2.5 billion) annually by 2029. The initiative simplifies the organization to reallocate...
GlaxoSmithKline PLC Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
GlaxoSmithKline PLC is projected to report Q2 2026 revenue of $10.79 billion and earnings per share of $1.27, with the stock currently trading at $51.39...
GSK cancer drug Ris-Rez hits survival goal in pivotal Phase 3 trial
GSK announced Friday that its licensed cancer therapy, risvutatug rezetecan (Ris-Rez), met its primary endpoint of overall survival. The pivotal Phase 3 trial...
GSK completes £2B buyback, clears path for Blenrep US growth
GSK has completed its £2 billion share buyback program to reduce outstanding shares and enhance shareholder returns. The company is also pursuing a cash...
GSK secures Canada approval for Exdensur, first twice-yearly asthma biologic
Health Canada approved GSK’s Exdensur (depemokimab) for the treatment of severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. This...